Introduction: Regular long-term clinical follow-up is an important component of HIV care.
Objective: To describe the reasons for follow-up loss among patients enrolled in the HIV/AIDS program of a university hospital.
Materials And Methods: A nested case-control study was carried out on a retrospective cohort between January 1st, 2012 and July 31st, 2013.
Results: A group of 45 patients was selected; the incidence density rate of patients lost to follow-up was 17.7 per 100 patient/years. The following variables were significantly linked to follow-up loss in the bivariate analysis: Unemployment (p=0.000); alcohol consumption (p=0.004); number of years of evolution of the disease (p=0.032); gender (p=0.027), and mean age of 34 years (p=0.000). When logistic regression was adjusted for the probability of follow-up loss the significant variables were: Mean age of 34 years (p=0.019, 95% CI: 0.871-0.976); female (p=0.017, 95% CI: 1.903-31.83); alcohol consumption (p=0.028, 95% CI: 0.040-0.830), and unemployment (p=0.001, 95% CI: 4.696-464.692).
Conclusions: HIV/AIDS programs need to establish follow-up systems and means to trace any losses in order to establish strategies to improve patient retention and, thus, their long-term quality of life.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.7705/biomedica.v36i2.2939 | DOI Listing |
Background: The adjunctive use of connective tissue grafts (CTGs) in the periodontal regeneration of intrabony defects has been proposed to prevent or limit postoperative gingival recession. However, there is limited evidence regarding the long-term clinical performance of this approach.
Methods: This article presents the five-year follow-up outcomes of a combination therapy using CTG, bone substitutes, and biologics for the treatment of deep intrabony defects associated with gingival recession.
J Chin Med Assoc
September 2024
Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Background: Many studies have reported the renal outcomes and metabolic consequences after augmentation cystoplasty (AC), however few studies have discussed changes in renal tubular function. The aim of this study was to determine the prevalence of metabolic disturbances, evaluate renal tubular function and 24-hour urine chemistry to evaluate the association between metabolic alterations and urolithiasis after AC.
Methods: We investigated serum biochemistry, blood gas, and 24-hour urinary metabolic profile of children who underwent AC between January 2000 and December 2020.
Int Urol Nephrol
January 2025
Department of Urology, Zealand University Hospital, Roskilde, Denmark.
Objective: To compare operative and oncological outcomes, as well as the risk of postoperative complications in patients who underwent transperitoneal robot-assisted partial nephrectomy (RAPN) for renal tumours located either posteriorly or anterolaterally.
Methods: Retrospective, consecutive study including 451 patients who underwent transperitoneal RAPN for non-metastatic, localised renal tumours from May 2016 to April 2023. Operative data included duration of the procedure, warm ischaemia time, and blood loss; oncological data included surgical margins and recurrence; and 90-day postoperative complications were classified according to the Clavien-Dindo classification.
Background: Abdominoplasty may be considered a procedure performed after a patient has already lost weight, but many surgeons have clinically observed that patients continue to lose weight in the postoperative period. This study sought to quantify continued weight loss after abdominoplasty procedures.
Methods: A retrospective chart review was conducted on all abdominoplasty cases performed by the senior author between 2018 and 2022.
Aliment Pharmacol Ther
January 2025
Department of Internal Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Background: Dropout is common and affects the statistical power and randomization balance of randomised controlled trials (RCTs).
Aims: To estimate the dropout rate in RCTs of metabolic dysfunction-associated steatohepatitis (MASH) and to examine factors associated with dropout in placebo-treated participants.
Methods: PubMed and Cochrane databases were searched for phase 2-4 MASH RCTs with placebo arms through November 24, 2024.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!